imatinib mesylate has been researched along with Neoplasm Seeding in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barsh, SR; Brennan, RC; Coppess, W; Flores-Otero, J; Garcia-Vargas, A; Goldsmith, ZK; Irvine, AS; Martinez-Ferrer, M; McEwen, MW; Morales-Tirado, VM; Ritter, MK; Wilson, MW; Yuan, K | 1 |
| Bartsch, DK; Fendrich, V | 1 |
| Alvegård, T; Bauer, S; Cameron, S; Eriksson, M; Hohenberger, P; Joensuu, H; Leinonen, M; Reichardt, A; Reichardt, P; Rejmyr Davis, M; Schütte, J; Sundby Hall, K | 1 |
| Chang, I; Choi, D; Kim, KM; Lee, JY; Lee, WJ; Sohn, TS; Yoo, EY | 1 |
| Corless, CL; Demetri, GD; Fisher, DE; Friedlander, P; Heinrich, MC; Hodi, FS; Jagannathan, J; Kruse, A; Mac Rae, S; Van den Abbeele, AD; Velazquez, EF | 1 |
1 review(s) available for imatinib mesylate and Neoplasm Seeding
| Article | Year |
|---|---|
[Gastrointestinal stromal tumors: diagnostics and therapy].
Topics: Benzamides; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Guideline Adherence; Humans; Imatinib Mesylate; Lymph Node Excision; Neoplasm Seeding; Neoplasm Staging; Piperazines; Pyrimidines; Risk Assessment | 2014 |
1 trial(s) available for imatinib mesylate and Neoplasm Seeding
| Article | Year |
|---|---|
Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour - Does it increase the risk for tumour cell seeding and recurrence?
Topics: Abdominal Wall; Antineoplastic Agents; Biopsy, Needle; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Neoplasm Recurrence, Local; Neoplasm Seeding; Protein Kinase Inhibitors; Risk Factors; Tomography, X-Ray Computed | 2016 |
3 other study(ies) available for imatinib mesylate and Neoplasm Seeding
| Article | Year |
|---|---|
Targeting the Platelet-Derived Growth Factor-beta Stimulatory Circuitry to Control Retinoblastoma Seeds.
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Drug Delivery Systems; Enzyme-Linked Immunosorbent Assay; Eye Enucleation; Flow Cytometry; Humans; Imatinib Mesylate; Immunohistochemistry; Neoplasm Seeding; NF-kappa B; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Receptor, Platelet-Derived Growth Factor beta; Retinal Neoplasms; Retinoblastoma; Retrospective Studies; Signal Transduction; Tumor Cells, Cultured; Vitreous Body | 2018 |
Residual and recurrent gastrointestinal stromal tumors with KIT mutations: findings at first follow-up CT after imatinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Female; Follow-Up Studies; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm, Residual; Peptide Fragments; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Splenic Neoplasms; Tomography, X-Ray Computed | 2009 |
Major response to imatinib mesylate in KIT-mutated melanoma.
Topics: Aged; Anastomosis, Surgical; Antineoplastic Agents; Benzamides; Female; Humans; Imatinib Mesylate; Melanoma; Mutation; Neoplasm Recurrence, Local; Neoplasm Seeding; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Rectal Neoplasms | 2008 |